nicht kleckern ..klotzen ::POZEN


Seite 5 von 5
Neuester Beitrag: 25.04.21 13:11
Eröffnet am:22.07.13 11:52von: buranAnzahl Beiträge:108
Neuester Beitrag:25.04.21 13:11von: SabinedhcuaLeser gesamt:17.928
Forum:Hot-Stocks Leser heute:3
Bewertet mit:
1


 
Seite: < 1 | 2 | 3 | 4 |
>  

246516 Postings, 6865 Tage buranPOZEN Inc. Announces Stockholder Approval of its

 
  
    #101
08.02.16 08:45
Transaction with Tribute Pharmaceuticals Canada Inc.
15:05 02.02.16

PR Newswire

CHAPEL HILL, N.C., Feb. 2, 2016

-Transaction Expected to Close on or About February 5, 2016-

CHAPEL HILL, N.C., Feb. 2, 2016 /PRNewswire/ -- POZEN Inc. ("POZEN") (NASDAQ: POZN), a specialty pharmaceutical company, today announced that its stockholders approved the Agreement and Plan of Merger and Arrangement (the "Merger Agreement") with Tribute Pharmaceuticals Canada Inc. ("Tribute") and the carrying out of the transactions contained therein. Upon closing of the transaction, the POZEN and Tribute businesses will operate as subsidiaries of Aralez Pharmaceuticals Inc. ("Aralez"), a company domiciled in Canada.

The Merger Agreement was also adopted by the Tribute shareholders on February 1, 2016. The proposed transaction remains subject to certain conditions and approvals, including approval of the Ontario Superior Court of Justice, listing of Aralez shares and customary closing conditions, and is expected to occur promptly following satisfaction of all conditions. Aralez will be listed on the NASDAQ stock exchange under the ticker symbol "ARLZ" and is expected to begin trading on or about February 8, 2016, and will be listed on the Toronto Stock Exchange ("TSX") under the ticker symbol "ARZ" and is expected to begin trading on on or about February 10, 2016, assuming closing on February 5, 2016. http://www.ariva.de/news/...ribute-Pharmaceuticals-Canada-Inc-5634621  

Optionen

246516 Postings, 6865 Tage buranMILTON, Ontario, Feb. 5, 2016

 
  
    #102
08.02.16 08:47
POZEN And Tribute Combine To Create Aralez Pharmaceuticals Inc.
19:20 05.02.16

PR Newswire

MILTON, Ontario, Feb. 5, 2016

-Transformative Transaction Creates Premier Specialty Pharma Company with a Broad Product Portfolio-

-Canadian Domicile Provides Compelling Platform for Growth with Competitive Structure-

-US$350 Million Capital Commitment from Deerfield-Led Syndicate-

MILTON, Ontario, Feb. 5, 2016 /PRNewswire/ -- Aralez Pharmaceuticals Inc. ("Aralez") today announced the completion of the business combination of POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ("Tribute") following approval of the transaction by stockholders of POZEN and shareholders of Tribute. The combined company will operate under Aralez Pharmaceuticals Inc. ("Aralez"), a global specialty pharmaceutical company with operations in Canada, Ireland and the United States. Under the terms of the Agreement and Plan of Merger and Arrangement, each share of POZEN common stock has been converted into the right to receive one Aralez common share and each common share of Tribute (other than dissenting shares) has been exchanged for 0.1455 Aralez common shares. http://www.ariva.de/news/...Create-Aralez-Pharmaceuticals-Inc-5639523  

Optionen

246516 Postings, 6865 Tage burangrosse Augen

 
  
    #103
12.02.16 14:06

246516 Postings, 6865 Tage burannicht kleckern ..klotzen ::POZEN

 
  
    #104
28.06.16 17:29
kein aktueller Kurs verfügbar ,GrB
 

Optionen

246516 Postings, 6865 Tage buranbestätigen

 
  
    #105
11.10.16 21:01
kein aktueller Kurs verfügbar ,GrB
 

Optionen

3663 Postings, 3276 Tage Xaropebestätige

 
  
    #106
11.10.16 21:03
hier in bayern auch kein kurs
wie schauts im norden aus?  

Optionen

246516 Postings, 6865 Tage buranAbteilung Inneres graphisch im Sektor Xarope #06

 
  
    #107
14.03.17 21:46
..klick und denn navigieren ..Route diagonal ..nein ..einfach plan rüber ..Einsicht auf Ende rechter Hand http://www.ariva.de/chart/?secu=6815  

Optionen

246516 Postings, 6865 Tage buranPOZEN Inc. is a small pharmaceutical company that

 
  
    #108
09.09.17 23:27
specializes in developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization. By utilizing a unique in-source model and focusing on integrated therapies, POZEN has successfully developed and obtained FDA approval of two self-invented products. Funded by these milestones/royalty streams, POZEN has created a portfolio of cost-effective, evidence-based integrated aspirin therapies designed to enable the full power of aspirin by reducing its GI damage. http://www.ariva.de/news/...eports-First-Quarter-2015-Results-5361986  

Optionen

Seite: < 1 | 2 | 3 | 4 |
>  
   Antwort einfügen - nach oben